The US food and drug administration perspective on cancer biomarker development

被引：141
|
作者：
Gutman, Steven
Kessler, Larry G.
机构：
[1] US FDA, Off In Vitro Diagnost Devices, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA
[2] US FDA, Off Sci, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA
[3] US FDA, Engn Labs, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA
来源：
NATURE REVIEWS CANCER | 2006年 / 6卷 / 07期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1038/nrc1911
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Despite the intense interest in biomarker development for cancer management, few biomarker assays for diagnostic uses have been submitted to the US Food and Drug Administration (FDA). What challenges must researchers overcome to bring cancer-detection technologies to the market and, therefore, into clinical use?
引用
收藏
页码：565 / 571
页数：8
相关论文
共 50 条
  • [41] Crisis deepens at the US Food and Drug Administration
    Lenzer, J
    BRITISH MEDICAL JOURNAL, 2004, 329 (7478): : 1308 - 1308
  • [42] Enrichment Strategies in Pediatric Drug Development: An Analysis of Trials Submitted to the US Food and Drug Administration
    Green, Dionna J.
    Liu, Xiaomei I.
    Hua, Tianyi
    Burnham, Janelle M.
    Schuck, Robert
    Pacanowski, Michael
    Yao, Lynne
    McCune, Susan K.
    Burckart, Gilbert J.
    Zineh, Issam
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) : 983 - 988
  • [43] US Food and Drug Administration Support for Oncology Drug Development During COVID-19
    Kadakia, Kushal T.
    Pazdur, Richard
    Shah, Anand
    JAMA ONCOLOGY, 2021, 7 (01) : 27 - 28
  • [44] Moving the US Food and Drug Administration Forward
    Perlmutter, Joel S.
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (11) : 1626 - 1627
  • [45] Cyberpharmacies and the role of the US Food And Drug Administration
    Henney, Jane E.
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2001, 3 (01) : 7 - 20
  • [46] The US Food and Drug Administration and Emergency Contraception
    Anthony W. Fox
    International Journal of Pharmaceutical Medicine, 2005, 19 (3) : 139 - 140
  • [47] Blueprint for Transparency at the US Food and Drug Administration
    McClellan, Courtney
    JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 1 - 1
  • [48] Opportunities and Challenges for the US Food And Drug Administration
    Kavanaugh, Claudine J.
    JOURNAL OF NUTRIGENETICS AND NUTRIGENOMICS, 2009, 2 (4-5) : 203 - 203
  • [49] Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development
    Hwang, T. J.
    Franklin, J. M.
    Kesselheim, A. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (02) : 290 - 296
  • [50] Food-Drug Effects and Pediatric Drug Development Studies Submitted to the US Food and Drug Administration, 2012-2022
    Tunehag, Kayla R.
    George, Blessy
    Samuels, Sherbet
    Vo, Karen
    Arya, Vikram
    Abulwerdi, Gelareh
    Burckart, Gilbert J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (06): : 697 - 703
12345